夏荔芪胶囊联合非那雄胺治疗良性前列腺增生症的临床研究

Clinical study on Xialiqi Capsules combined with finasteride in treatment of benign prostatic hyperplasia

目的探讨夏荔芪胶囊联合非那雄胺片治疗良性前列腺增生症的临床疗效。方法选取2017年10月-2019年1月首都医科大学附属北京康复医院收治的100例良性前列腺增生症患者为研究对象,将全部患者按照随机数字表法分为对照组和治疗组,每组各50例。对照组口服非那雄胺片,5mg/次,1次/d。治疗组在对照组治疗的基础上口服夏荔芪胶囊,3粒/次,3次/d。两组患者连续治疗12周。观察两组的临床疗效,比较两组国际前列腺症状评分表(I-PSS)评分、前列腺体积、残余尿量、尿流率、细胞因子水平、生活质量。结果治疗后,对照组和治疗组的总有效率分别为80.00%、94.00%,两组比较差异有统计学意义(P<0.05)。治疗后,两组的I-PSS评分、前列腺体积、残余尿量均显著降低,尿流率显著升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗后,治疗组的I-PSS评分、前列腺体积、残余尿量均低于对照组,尿流率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组的白细胞介素-17(IL-17)、前列腺素E2(PGE2)、前列腺特异抗原(PSA)、高敏C反应蛋白(hs-CRP)水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗后,治疗组的IL-17、PGE2、PSA、hs-CRP水平明显低于对照组,差异有统计学意义(P<0.05)。治疗后,两组的生活质量量表(QOL)评分显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗后,治疗组的QOL评分比对照组低,差异有统计学意义(P<0.05)。结论夏荔芪胶囊联合非那雄胺片治疗良性前列腺增生症具有较好的临床疗效,可改善临床症状和生活质量,减轻炎症反应,具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Xialiqi Capsules combined with Finasteride Tablets in treatment of benign prostatic hyperplasia. Methods Patients(100 cases) with benign prostatic hyperplasia in Beijing Rehabilitation Hospital of Capital Medical University from October 2017 to January 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Finasteride Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Xialiqi Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and I-PSS score, prostate volume, residual urine volume, urinary flow rate, cytokine levels, and quality of life in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 94.00%, respectively, and there was difference between two groups(P < 0.05). After treatment, I-PSS score, prostate volume, and residual urine volume in two groups were significantly decreased, but the urinary flow rate in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of IL-17, PGE2, PSA, and hs-CRP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, QOL scores in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the QOL score in the treatment group were significantly lower than that in the control group, with significant difference between two groups(P < 0.05). Conclusion Xialiqi Capsules combined with Finasteride Tablets has clinical curative effect in treatment of benign prostatic hyperplasia, can improve clinical symptoms and quality of life, and alleviate inflammation, which has a certain clinical application value.